Evidence map›Paper›PMID 27743888›Full record

Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2017

Heart Dose Is an Independent Dosimetric Predictor of Overall Survival in Locally Advanced Non-Small Cell Lung Cancer.

Christina K Speirs, Todd A DeWees, Sana Rehman, Alerson Molotievschi, Maria A Velez, Daniel Mullen, Sandra Fergus, Marco Trovo, Jeffrey D Bradley, Cliff G Robinson

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04846309 (Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy), which is not on this map. Cited by 146 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 4 pooled it
18.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04846309 phase1recruitingnot on this mapstarted 2021, after this paper: background citation

Hypoxia Imaging for Esophageal Cancer to Guide Personalized Radiation Therapy

TypeinterventionalSponsorUniversity of UtahRan2021 to 2027Enrolled16ConditionsEsophageal CancerArmsRadiation, FMISO PET CT
3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 4 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Biomarkers associated with pulmonary exacerbations in a randomized trial of nintedanib for radiation pneumonitis.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024
    Trial
  7. Trial
  8. Trial
  9. Modeling the Impact of Cardiopulmonary Irradiation on Overall Survival in NRG Oncology Trial RTOG 0617.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020
    Trial
  10. Trial
  11. Trial
  12. Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Trial
  13. Review
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Article
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Christina K SpeirsDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Todd A DeWeesDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Sana RehmanDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Alerson MolotievschiClinicas Oncologicas Integradas, Rio de Janeiro, Brazil.
Maria A VelezDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Daniel MullenDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Sandra FergusDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Marco TrovoDepartment of Radiation Oncology, Centro di Referimento Oncologico Aviano, Aviano, Italy.
Jeffrey D BradleyDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri.
Cliff G RobinsonDepartment of Radiation Oncology, Siteman Cancer Center, Washington University/Barnes Jewish Hospital, Saint Louis, Missouri. Electronic address: crobinson@radonc.wustl.edu.
Barnes-Jewish Hospital · USJewish Hospital · USCentro di Riferimento Oncologico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionIn the randomized trial of standard- versus high-dose chemoradiotherapy for locally advanced (LA) NSCLC (Radiation Therapy Oncology Group 0617), overall survival (OS) was worse in the high-dose arm. Although heart dose was suggested as a contributing factor, actionable parameters have not been established. We present an analysis of clinical and dosimetric parameters affecting OS in this patient population, focusing on heart dose.

methodsClinical data were collected on 416 patients with LA NSCLC treated at a single institution, with a subset of 333 available treatment plans recontoured using Radiation Therapy Oncology Group 0617 normal tissue guidelines. Toxicity and dosimetry data were analyzed for 322 patients; multivariate analysis was performed on 251 patients. Dosimetric parameters of radiation to tumor and organs at risk were analyzed with clinical data pertaining to OS, disease-free survival, and toxicity.

resultsPatients were treated with radiation therapy to prescribed doses of 50.0 to 84.9 Gy (median 66.0 Gy). Median follow-up was 14.5 months. Median OS was 16.8 months. The 1- and 2-year OS rates were 61.4% and 38.8%, respectively. On multivariate analysis, factors independently associated with worse OS were increasing heart V

conclusionsHeart dose is associated with OS and cardiac toxicity for patients with LA NSCLC treated with chemoradiotherapy.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellChemoradiotherapyFemaleFollow-Up StudiesHeartHumansLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingOrgans at RiskCardiac toxicityNSCLCRadiation dosimetryRadiation therapySurvival outcomes

Identifiers

PMID27743888
OpenAlexW2531388082

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.